logo
  Join        Login             Stock Quote

Hologic To Participate In Three Investor Conferences

Monday, February 7, 2011 4:19 PM


BEDFORD, Mass., Nov. 10, 2010 /PRNewswire-FirstCall/ -- Hologic, Inc. (Nasdaq: HOLX) today announced that company management will participate in the following conferences:

  • Rob Cascella, President and Chief Executive Officer, will present at the J.P. Morgan SMid Conference in New York City on Thursday, December 2, 2010, at 4:30 p.m. (Eastern). Interested parties are invited to listen to the live audio webcast of Hologic's investor presentation on the investor section of the company's website at www.hologic.com/investors-overview. An archive of the presentation will be available for replay following the conference.
  • Glenn Muir, Executive Vice President and Chief Financial Officer, will host investor meetings at the Lazard Capital Markets Medical Technology Corporate Access Day in Denver on Thursday, December 2, 2010. Management will not be presenting at this conference and therefore there will be no webcast.
  • Deborah Gordon, Vice President of Investor Relations, will host investor meetings at the Nasdaq OMX 25th Investor Program in London on Tuesday, December 7, 2010. Management will not be presenting at this conference and therefore there will be no webcast.

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast Magnetic Resonance Imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications. For more information, visit www.hologic.com.

Contact:

Deborah Gordon


Vice President, Investor Relations


Hologic, Inc.


(781) 999-7716



SOURCE Hologic, Inc.

Deborah Gordon, Vice President, Investor Relations, Hologic, Inc., +1-781-999-7716

(Source: PR Newswire )
(Source: Quotemedia)

Advertisement
Advertisement



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.